Find the right fit for you - faster
Get tailored insights about working at Serenex in one quick step.
Serenex Snapshot
Serenex knows cancer patients know little serenity as they battle their disease. The company develops in-house, and licenses from other drug companies, potential therapies for various forms of cancer and inflammatory diseases. Serenex's drug candidates, based on the company's proprietary Heat Shock Protein 90 (Hsp90) technology, could also have neurodegenerative and antiviral applications. The product furthest along is SNX-5422, a drug that is activated inside a tumor where it inhibits protein activity necessary for tumor cell growth. Serenex was acquired by Pfizer in 2008.
